OBJECTIVES: The full potential of stereotactic body radiation therapy (SBRT), in the treatment of unresectable intrahepatic malignancies, has yet to be realized as our experience is still limited. Thus, we evaluated SBRT outcomes for primary and metastatic liver tumors, with the goal of identifying factors that may aid in optimization of therapy. METHODS: From 2005 to 2010, 62 patients with 106 primary and metastatic liver tumors were treated with SBRT to a median biologic effective dose (BED) of 100 Gy (42.6-180). The majority of patients received either three (47%) or five fractions (48%). Median gross tumor volume (GTV) was 8.8 cm(3) (0.2-222.4). RESULTS: With a median follow-up of 18 months (0.46-46.8), freedom from local progression (FFLP) was observed in 97 of 106 treated tumors, with 1- and 2-year FFLP rates of 93% and 82%. Median overall survival (OS) for all patients was 25.2 months, with 1- and 2-year OS of 81% and 52%. Neither BED nor GTV significantly predicted for FFLP. Local failure was associated with a higher risk of death [hazard ratio (HR) = 5.1, P = .0007]. One Child-Pugh Class B patient developed radiation-induced liver disease. There were no other significant toxicities. CONCLUSIONS: SBRT provides excellent local control for both primary and metastatic liver lesions with minimal toxicity. Future studies should focus on appropriate selection of patients and on careful assessment of liver function to maximize both the safety and efficacy of treatment.
OBJECTIVES: The full potential of stereotactic body radiation therapy (SBRT), in the treatment of unresectable intrahepatic malignancies, has yet to be realized as our experience is still limited. Thus, we evaluated SBRT outcomes for primary and metastatic liver tumors, with the goal of identifying factors that may aid in optimization of therapy. METHODS: From 2005 to 2010, 62 patients with 106 primary and metastatic liver tumors were treated with SBRT to a median biologic effective dose (BED) of 100 Gy (42.6-180). The majority of patients received either three (47%) or five fractions (48%). Median gross tumor volume (GTV) was 8.8 cm(3) (0.2-222.4). RESULTS: With a median follow-up of 18 months (0.46-46.8), freedom from local progression (FFLP) was observed in 97 of 106 treated tumors, with 1- and 2-year FFLP rates of 93% and 82%. Median overall survival (OS) for all patients was 25.2 months, with 1- and 2-year OS of 81% and 52%. Neither BED nor GTV significantly predicted for FFLP. Local failure was associated with a higher risk of death [hazard ratio (HR) = 5.1, P = .0007]. One Child-Pugh Class B patient developed radiation-induced liver disease. There were no other significant toxicities. CONCLUSIONS: SBRT provides excellent local control for both primary and metastatic liver lesions with minimal toxicity. Future studies should focus on appropriate selection of patients and on careful assessment of liver function to maximize both the safety and efficacy of treatment.
Authors: K K Herfarth; J Debus; F Lohr; M L Bahner; B Rhein; P Fritz; A Höss; W Schlegel; M F Wannenmacher Journal: J Clin Oncol Date: 2001-01-01 Impact factor: 44.544
Authors: Edgar Ben-Josef; Daniel Normolle; William D Ensminger; Suzette Walker; Daniel Tatro; Randall K Ten Haken; James Knol; Laura A Dawson; Charlie Pan; Theodore S Lawrence Journal: J Clin Oncol Date: 2005-12-01 Impact factor: 44.544
Authors: Tracey E Schefter; Brian D Kavanagh; Robert D Timmerman; Higinia R Cardenes; Anna Baron; Laurie E Gaspar Journal: Int J Radiat Oncol Biol Phys Date: 2005-08-01 Impact factor: 7.038
Authors: Daniel T Chang; Anand Swaminath; Margaret Kozak; Julie Weintraub; Albert C Koong; John Kim; Rob Dinniwell; James Brierley; Brian D Kavanagh; Laura A Dawson; Tracey E Schefter Journal: Cancer Date: 2011-03-22 Impact factor: 6.860
Authors: June L Chan; Susan W Lee; Benedick A Fraass; Daniel P Normolle; Harry S Greenberg; Larry R Junck; Stephen S Gebarski; Howard M Sandler Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: Kyle E Rusthoven; Brian D Kavanagh; Stuart H Burri; Changhu Chen; Higinia Cardenes; Mark A Chidel; Thomas J Pugh; Madeleine Kane; Laurie E Gaspar; Tracey E Schefter Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: Theodore H Welling; Mary Feng; Shanshan Wan; Sin Ye Hwang; Michael L Volk; Theodore S Lawrence; Mark M Zalupski; Christopher J Sonnenday Journal: Liver Transpl Date: 2013-11-21 Impact factor: 5.799
Authors: Daniel R Wahl; Matthew H Stenmark; Yebin Tao; Erqi L Pollom; Elaine M Caoili; Theodore S Lawrence; Matthew J Schipper; Mary Feng Journal: J Clin Oncol Date: 2015-11-30 Impact factor: 44.544
Authors: Eli Sapir; Yebin Tao; Matthew J Schipper; Latifa Bazzi; Paula M Novelli; Pauline Devlin; Dawn Owen; Kyle C Cuneo; Theodore S Lawrence; Neehar D Parikh; Mary Feng Journal: Int J Radiat Oncol Biol Phys Date: 2017-09-14 Impact factor: 7.038
Authors: Victor W Wu; Marina A Epelman; Hesheng Wang; H Edwin Romeijn; Mary Feng; Yue Cao; Randall K Ten Haken; Martha M Matuszak Journal: Phys Med Biol Date: 2016-08-12 Impact factor: 3.609
Authors: You Zhang; Michael R Folkert; Xiaokun Huang; Lei Ren; Jeffrey Meyer; Joubin Nasehi Tehrani; Robert Reynolds; Jing Wang Journal: Quant Imaging Med Surg Date: 2019-07
Authors: Krithika Suresh; Dawn Owen; Latifa Bazzi; William Jackson; Randall K Ten Haken; Kyle Cuneo; Mary Feng; Theodore S Lawrence; Matthew J Schipper Journal: Int J Radiat Oncol Biol Phys Date: 2017-09-22 Impact factor: 7.038
Authors: Issam El Naqa; Adam Johansson; Dawn Owen; Kyle Cuneo; Yue Cao; Martha Matuszak; Latifa Bazzi; Theodore S Lawrence; Randall K Ten Haken Journal: Int J Radiat Oncol Biol Phys Date: 2018-02-01 Impact factor: 7.038